Covidien reviews

-Poor strategy and management decisions have led to loss of talented employees -Covidien's decision to spin-off pharma due to drag on financials, lack of viable/sustainable pipeline projects, short-lived patent protection with weak prospects to fill void -Declining financials due to high costs and more innovative competitors -Non-global and highly dependent on US market -Company does not value diversity and is a rare haven for the typical young white male, however company is trying to mask this and have placed token women in VP positions -Who you know, not what you know, is the key to advancement -Very high turnover of upper-level management -Lack of innovation and industry leadership, me-too company -Unstable company

There was recently a big layoff. While a lot of people who had been around for years and no longer contributed much were let go the management also took the chance to get rid of anyone who offered opinions differing from theirs. I saw some of my colleagues who, in internal departmental meetings, would proposed changes or different ideas than directors and VPs but go along with the VPs decision in front of the rest of the company get let go. It seemed really petty and now no one offers dissenting views. Creativity for the entire R&D organization has been put on notice.